Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
NCT07897240Phase 1Not yet recruiting
- Sponsor
- Triastek
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of D23A in IgA nephropathy (IgAN) (2 arms), sponsored by Triastek. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last quantifiable concentration and 10 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
D23A
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07897240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897240.